Remove 2013 Remove DNA Remove Virus
article thumbnail

PRITELIVIR MESYLATE

New Drug Approvals

1428321-10-1 Pritelivir mesylate is an antiviral drug currently under development, specifically targeting herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Pritelivir (development codes AIC316 or BAY 57-1293 ) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV).

Virus 62
article thumbnail

Women in Stem with Dr Emily Leproust

Drug Target Review

After some time in that role and launching several products, I received a call from Bill Banyai and Bill Peck, or ‘The Bills’ as we call them, who were building a company around technology that creates DNA by ‘writing’ it on a silicon chip. Twist was officially founded in 2013. At that time synesthetic biology wasn’t cool.

DNA 116
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gene editing extends lifespan in mouse model of prion disease

Broad Institute

The treatment, which uses base editing to make a single-letter change in DNA, reduced levels of the disease-causing prion protein in the brain by as much as 60 percent. The wife-and-husband team started a lab at the Broad with a singular focus: preventing and treating prion disease within their lifetime.

Disease 144
article thumbnail

Addressing increasingly resistant drugs by infectious agents

Drug Target Review

Infectious agent includes bacteria, virus, fungi, and parasites, and they are capable of causing disease in a living organism. I had earlier proposed the use of Palmatine and Silver Nitrate in the efficacy against the RNA structure of the COVID-19 virus. We discovered it is highly effective and environmentally friendly. Guillermo, S.,

Drugs 111
article thumbnail

Cave Coronavirus in Wuhan Lab Seeded COVID – The Truth Has Always Been Out There, in the Genetics

PLOS: DNA Science

The virus SARS-CoV-2 emerged in Wuhan, home of a premiere research institute that focuses on viruses. Experiments at the Wuhan facility were done at the lowest two of the four standard biosafety levels, which were established at the dawn of recombinant DNA research in the 1970s. An altered virus could have escaped. Coincidence?

Virus 52
article thumbnail

AI in gene delivery vector discovery and design

Drug Target Review

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. Molecular therapy 21 , 109-118 (2013). Grimm D, et al.

article thumbnail

HOOKIPA Announces Positive Phase 2 Interim Safety, Immunogenicity, and Efficacy Data for its Cytomegalovirus Vaccine Candidate HB-101

The Pharma Data

Compared to placebo, participants vaccinated with three HB-101 doses had: a 48 percent reduction in CMV viremia (presence of CMV DNA in the blood); a 42 percent reduction in the use of antiviral therapy; and. 3 The majority of CMV infections are not serious, and the virus can lay dormant in the body for years.

Vaccine 40